International Laboratory Branch, Division of Global HIV/AIDS, Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, GA 30329, USA.
J Clin Microbiol. 2011 Oct;49(10):3470-3. doi: 10.1128/JCM.01122-11. Epub 2011 Aug 10.
The HIV-1 BED incidence assay was developed at the Centers for Disease Control and Prevention and since 2005 has been available as a commercial kit for use in HIV-1 incidence surveillance. A BED-specific proficiency testing (PT) program was initiated in 2006 that included a panel of eight coded specimens (six unique and two duplicates) to participating laboratories. The number of participating laboratories increased from 12 to 38 from 2006 to 2009. Overall, 96.1% of the laboratories reported results, and 95.4% of those reporting achieved a 100% score. The observed mean normalized optical density (OD-n) values of all participants correlated well with the expected OD-n values for all specimens (R(2) = 0.98) used for seven PT rounds. BED testing demonstrated high reproducibility among all laboratories, with an agreement of 99.3% (574/578) between initial and confirmatory classification and regression statistics of R(2) = 0.96, slope = 1.022, and intercept = 0.0066. Reproducibility among duplicate specimens was very high during each PT round, with mean deviation of 1.8%. Analysis of controls and calibrator specimen for all 343 runs showed a coefficient of variation of ca. 20% for raw ODs in the dynamic range, which was reduced to <10% when the OD was normalized (OD-n). Most laboratories that failed the PT assessment had transcriptional errors, kit reagent problems, or specimen handling errors. Thus, the BED-specific PT program enabled us to track performance of different laboratories conducting the BED assay while identifying areas for improvements. This program will also serve as a template for future PT programs for new incidence assays as they become available.
HIV-1 BED 发生率检测法由疾病控制与预防中心开发,自 2005 年以来,已作为一种商业试剂盒用于 HIV-1 发生率监测。2006 年启动了 BED 特异性能力验证(PT)计划,其中包括一个包含八个编码样本(六个独特样本和两个重复样本)的小组,分发给参与实验室。从 2006 年到 2009 年,参与实验室的数量从 12 个增加到 38 个。总体而言,96.1%的实验室报告了结果,其中 95.4%的实验室达到了 100%的分数。所有参与者的观察到的平均归一化光密度(OD-n)值与所有用于七个 PT 轮次的样本(R(2) = 0.98)的预期 OD-n 值相关性良好。BED 测试在所有实验室中表现出高度的可重复性,初始和确认分类之间的一致性为 99.3%(574/578),回归统计的 R(2) = 0.96,斜率= 1.022,截距= 0.0066。在每个 PT 轮次中,重复样本之间的重复性非常高,平均偏差为 1.8%。对所有 343 次运行的对照和校准样本的分析表明,在动态范围内,原始 OD 的变异系数约为 20%,当 OD 归一化(OD-n)时,该值降低到<10%。大多数未能通过 PT 评估的实验室存在转录错误、试剂盒试剂问题或样本处理错误。因此,BED 特异性 PT 计划使我们能够跟踪进行 BED 检测的不同实验室的性能,同时确定需要改进的领域。该计划还将为未来新的发生率检测方法的 PT 计划提供模板,随着新的方法的出现。